Below are current clinical trials.8 studies in Multiple sclerosis
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to compare the effectiveness and safety of ofatumumab given by injection every 4 weeks, compared to teriflunomide given orally once daily to patients who have relapsing type (returns and worsens unpredictably) multiple sclerosis.
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
The study is designed to quantitate McArdle's sign, an increase in measurable weakness with neck flexion described in patients with multiple sclerosis, and to determine whether it is or is not specific for multiple sclerosis.
The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put children and adolescents at risk for getting MS.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of this study is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), urine, stool, DNA and tissue specimens collected from patients who have central nervous system (CNS) inflammatory diseases.
This study is being done to develop a data and specimen registry of pediatric patients in order to study the cause, early detection and best treatment for multiple sclerosis (MS).
The purpose of this study is to develop quantitative approaches of analyzing multimodal MRI acquisitions with the goal to improve cortical lesion detection in all stages in MS, and to understand the interplay between cortical lesions, white matter lesions and functional connectivity network disruptions.
The purpose of this study is to learn more about the diagnosis, course, and treatment of inflammatory CNS diseases using clinical information (for example, symptoms, neurological examination abnormalities, MRI and other test results) together with laboratory tests on blood and cerebrospinal fluid (fluid which surrounds the spinal chord and brain). Plan to follow study participants for 3 years, periodically obtaining updated clinical information and blood samples during that time.
Aug. 04, 2017
- AskMayoExpert. What is multiple sclerosis? Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Daroff RB, et al. Bradley's Neurology in Clinical Practice. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2012. https://www.clinicalkey.com. Accessed Dec. 16, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed April 4, 2014.
- Olek MJ. Epidemiology and clinical features of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed April 4, 2014.
- Wingerchuk DM (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. May 13, 2014.
- Kantarci O. Treatment of primary progressive multiple sclerosis. Seminars in Neurology. 2013;33:74.
- Keegan BM. Therapeutic decision making in a new drug era in multiple sclerosis. Seminars in Neurology. 2013;33:5.
- Goldman L, et al. Goldman's Cecil Medicine. 24th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. http://www.clinicalkey.com. Accessed April 4, 2014.
- Lotze TE. Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis. http://www.uptodate.com/home. Accessed April 5, 2014.
- Kantarci OH, et al. Novel immunomodulatory approaches for the management of multiple sclerosis. Clinical Pharmacology & Therapeutics. 2014;95:32.
- Olek MJ. Treatment of relapsing-remitting multiple sclerosis in adults. http://www.uptodate.com/home. Accessed Dec. 16, 2014.
- Olek MJ. Treatment of acute exacerbations of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed April 4, 2014.
- Wingerchuk DM. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clinic Proceedings. 2014;89:225.
- Pizzorno JE, et al. Textbook of Natural Medicine. 4th ed. St. Louis, Mo.: Churchill Livingstone Elsevier; 2013. https://www.clinicalkey.com. Accessed April 4, 2014.
- Olek MJ. Diagnosis of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed Jan. 2, 2015.
- Polman, C, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology. 2011;69:292. http://onlinelibrary.wiley.com/doi/10.1002/ana.22366/pdf.
- Patient information: Multiple sclerosis. http://www.uptodate.com/home. Accessed Jan. 2, 2015.
- Olek MJ. Symptom management of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed Jan. 2, 2015.
- Yadav Y, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. Neurology. 2014;82:1083.
- Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. Jan. 20, 2015.
- National MS Society. Network of Pediatric MS Centers. Accessed Feb. 10, 2015. http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS/Pediatric-MS/Care-for-Pediatric-MS-%28Centers-of-Excellence%29.
- Rodriguez M. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. 1993;43:1100.
- Deb C. CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLOS One. Aug. 30, 2010.
- FDA approves new drug to treat multiple sclerosis. FDA. Accessed March 29, 2017.